Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Indian Journal of Forensic Medicine & Toxicology
Suhad Hassan Aubaid1 , Ekhlas Saddam Falih2 , Zeina Anwar Jaffar3
Unknown Affiliation
Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Measuring of Interleukin -22 and IL -17a Levels in Seropositive and Seronegative Rheumatoid Arthritis Patients Suhad Hassan Aubaid1 , Ekhlas Saddam Falih2 , Zeina Anwar Jaffar3
Indian Journal of Forensic Medicine & Toxicology Vol. 14 No. 4 (2020): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v14i4.11894

Abstract

Background: “Rheumatoid arthritis (RA) is an inflammatory disease leading to joint disruption”. Theinstant study designed to detect serum markers in RA that could discriminate between seropositive (SP) andseronegative (SN) by evaluating levels of IL- 22and IL -17a in patients with rheumatoid arthritis. Methods:In this cross-sectional study, a total of sixty Rheumatoid arthritis (RA ) patients’ age and sex-matched withhealthy controls were involved in the present study. The serum IL- -22 and IL -17a levels were measuredusing an ELISA kit. Results: The mean ±SD age in seropositive and seronegative was (37.22± 11.29 and34.28±20.3 years, respectively), while in control group was (27.14±9.33 years). Furthermore, serum IL- 22and IL -17a level was significantly higher in seropositive and seronegative RA patients compared to healthycontrols (P<0.001). There was no significant variation in serum IL -22 and IL -17a level according to theseropositive and seronegative in RA patients (p>0.05), but there was a positive correlation between themROC test representing a highly sensitive and specific . Conclusion: The present study exhibited higherserum IL- 22 and IL -17a levels in seropositive and seronegative in RA patients compared to healthy controls.Therefore, IL- 22 and IL -17a can be considered as a biomarker for RA disease, with high sensitivity andspecificity but these cytokines couldn’t be used as discriminated between SP and SN in RA patients.
Co-Authors